Eggener S - Search Results

1

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.

Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. Weinstock C, et al. Among authors: eggener s. J Urol. 2020 Jan;203(1):115-119. doi: 10.1097/JU.0000000000000532. Epub 2019 Sep 10. J Urol. 2020. PMID: 31502940 Free PMC article.

2

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. Smith ND, et al. J Urol. 2003 Apr;169(4):1219-28. doi: 10.1097/01.ju.0000056085.58221.80. J Urol. 2003. PMID: 12629332 Review.

3

Renal tumors in young adults.

Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, Waters WB, Picken M, Campbell SC. Eggener SE, et al. J Urol. 2004 Jan;171(1):106-10. doi: 10.1097/01.ju.0000099028.95679.52. J Urol. 2004. PMID: 14665855

4

Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.

Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Kundu SD, et al. J Urol. 2004 Dec;172(6 Pt 1):2227-31. doi: 10.1097/01.ju.0000145222.94455.73. J Urol. 2004. PMID: 15538237

5

Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.

Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ. Eggener SE, et al. J Urol. 2005 Apr;173(4):1150-5. doi: 10.1097/01.ju.0000155158.79489.48. J Urol. 2005. PMID: 15758725

6

Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.

Eggener SE, Roehl KA, Catalona WJ. Eggener SE, et al. J Urol. 2005 Aug;174(2):500-4. doi: 10.1097/01.ju.0000165203.40973.0f. J Urol. 2005. PMID: 16006880

7

Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.

Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ. Eggener SE, et al. J Urol. 2006 Oct;176(4 Pt 1):1399-403. doi: 10.1016/j.juro.2006.06.045. J Urol. 2006. PMID: 16952643

8

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.

Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA. Yossepowitch O, et al. Among authors: eggener se. J Urol. 2007 Aug;178(2):493-9; discussion 499. doi: 10.1016/j.juro.2007.03.105. Epub 2007 Jun 11. J Urol. 2007. PMID: 17561152

9

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.

Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L; International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Eggener SE, et al. J Urol. 2007 Dec;178(6):2260-7. doi: 10.1016/j.juro.2007.08.072. Epub 2007 Oct 15. J Urol. 2007. PMID: 17936815 Review.

10

Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. Eggener SE, et al. Urology. 2008 Jun;71(6):1016-9. doi: 10.1016/j.urology.2007.12.008. Epub 2008 Mar 21. Urology. 2008. PMID: 18358515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Search Page

Filters